Personalis at Advances in Immuno-Oncology Europe Congress: MAY 20-21, 2019


Robert Power

Robert Power, MS
Product Manager

Tuesday, May 21 | 11:00 AM 

Advancing Precision Oncology Biomarker Discovery with a Multidimensional Immunogenomics Platform

Searching for more accurate predictors of patient response to cancer immunotherapy may depend on finding the right combination of biomarkers, yet few approaches enable multi-dimensional biomarker analysis.

  • The search continues to ascertain biomarkers that will improve the selection of patients who will best respond to immunotherapies and help tailor these promising treatments
  • The complexity of both the tumor and tumor microenvironment suggests a more comprehensive approach is needed for robust and accurate characterization of the cancer ecosystem
  • The ImmunoID NeXT platform consolidates multiple biomarker assays into one with the ability to detect neoantigens, characterize the immune repertoire and identify novel biomarker signatures from a single sample
  • We’ll discuss how to overcome barriers in translational research with this innovative assay design and optimized analytics for maximizing data generation for precision oncology